New Investment Opportunity: ProFuse

New Investment Opportunity: ProFuse

Accelerating the future of lab-grown meat

  • Substantially accelerates the production of lab-grown meat, reducing costs and making it more economically viable for large-scale production
  • Proprietary enhanced muscle generation technology, created at the Weizmann Institute, increases quality, texture and shortens growth timeline of cultivated meat
  • POCs with leading global cultivated meat producers
  • CEO is serial entrepreneur, leads experienced team of Weizmann Institute researchers and experts
  • Pre-revenue, early-stage startup nurtured at Israel's Fresh Start incubator
  • $2.5M SAFE round led by new external investor, Tnuva and Tempo reinvesting

Invest Now

BOOK A CALL
with your Investor Relations representative

Dear Josb,

The world's population is growing fast, threatening the future of global food supplies. Within 30 years, the meat industry will need to double its production to meet demand. Consumers are looking for meat alternatives to replace those produced from farm animals. Years ago, scientists began working on producing meat by growing cells in labs. They succeeded, but the process is long and expensive, making it impossible to produce a cost-effective, scalable product.

Our Crowd is investing in ProFuse, an Israeli startup based on years of research at the Weizmann Institute that has created the technology to produce lab-grown meat at scale. The details here are based on information received from, and verified solely by, the company.

The problem
Concerns about sustainability and the ethical treatment of animals are driving consumers to adopt alternative meat products to replace those produced from farm-grown livestock. This growing demand led to the birth of the lab-grown meat industry which uses cultured cells to produce products which have similar taste and nutritional value to farm-grown meat and are environmentally friendly. Unfortunately, this process is both costly and time consuming, rendering the business of cultured meat unviable.

The solution
ProFuse's technology develops muscle tissue of cultivated meat quicker and increases yields while improving the nutritional value of the final product. It targets a unique molecular signaling pathway which robustly regulates muscle cell differentiation, fusion and maturation. The development relies on six years of research conducted at the Weizmann Institute which established a detailed biochemical signaling pathway, and was proven in the lab for chicken, beef and lamb.

The sector
The cultivated meat industry is in its infancy, valued at $1.6M in 2021 and estimated to reach $140B by 2030, and $630B by 2040. The global demand for meat is increasing, especially in developing countries, as consumers adopt a more nutritional diet compatible with a sustainable lifestyle.

The team
Guy Nevo Michrowski, ProFuse's CEO and co-founder, is a serial entrepreneur with more than 20 years of experience in startups and the former VP Strategic Marketing of XPERI (NASDAQ:XPER). He leads a highly experienced team including the three Weizmann Institute scientists who conducted the research leading to the breakthrough. Dr. Tamar Eigler-Hirsh, CTO and scientific founder, holds a post-doc from Weizmann and has more than 20 years of research experience in the field of muscle development and regeneration.

The round
Proceeds from this $2.5M SAFE will be used to demonstrate how the technology can grow a whole cut of meat, chicken or similar, and demonstrate the utility of the ProFuse product in other species, particularly fish. ProFuse also plans to use the funds to expand its lab and R&D infrastructure, purchase a 2L bioreactor, and expand its R&D team.

Invest Now

Meet the CEO
We're hosting a webinar/conference call on Monday, April 11th, at 6PM Israel / 11AM New York / 8AM San Francisco for investors to meet CEO and Co-Founder Guy Nevo Michrowski and learn more about ProFuse.

Register Now

Can't make the webinar? Register and we will send you a recording of the call.

The ProFuse solution
ProFuse is developing a tissue culture differentiation media-additive for the evolving cultivated meat industry that optimizes the cultivation process and reduces costs. ProFuse reduces production time and proliferation media usage while increasing efficiency and biomass production, meaning that more muscle mass is produced from the same starting number of cells. This allows for lower costs as well as contributes to the final product's structure and protein content, which supports the industry's interest in reaching a product that is as closely similar as possible to animal sourced meat.

Next steps:

Invest Now

investor services-03-03-03
Best,
OurCrowd Investments 

How relevant was this email in helping you with your investment decisions?

Certain information in this email contains "forward-looking information" under applicable securities laws ("forward-looking statements"). These may include, among others, projected performance; expected development of the company's business, projects and partnerships; execution of the company's vision and growth strategy; and the like. Forward-looking statements are not guarantees of future performance and should not be relied on in any way. 

Nothing contained in and accompanying this communication shall be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security by OurCrowd, its portfolio companies or any third party. Information regarding OurCrowd's limited partnerships and/or portfolio companies and the investment opportunities on OurCrowd's website is intended and available for accredited investors only (criteria at OurCrowd). OurCrowd urges potential investors to consult with licensed legal professionals and investment advisors for any legal, tax, insurance, or investment advice.OurCrowd operates in Canada through OurCrowd Canada Inc., an exempt market dealer registered in the Provinces of British Columbia, Alberta, Manitoba, Ontario, Quebec and Nova Scotia.

Follow us:

social_A-1social_A-1social_B-1social_C-1

You received this email because you are subscribed to emails from OurCrowd.
Update your email preferences to choose the types of emails you receive. 

Post a Comment

0 Comments